UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

Healthcare Professionals

Patients

Investors

23 UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab

Read More Share:

Dec

13 Employee Spotlight: Leah VanderVeen and Her Time as a Court Appointed Special Advocate for Foster Children

Read More Share:

Dec

07 The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis

Read More Share:

Nov

22 UCB Submits Response to FDA Complete Response Letter for Bimekizumab

Read More Share:

Nov

14 UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients

Read More Share:

Oct

12 Advancing Science to Better Care for Epilepsy Patients

Read More Share:

Sep

26 UCB U.S. Headquarters in Atlanta Awarded Prestigious LEED Gold WELL Platinum Certifications

Read More Share:

Sep

26 UCB Achieves Two Awards Recognizing our Sustainability Efforts for the Atlanta Warehouse Expansion

Read More Share:

Sep

22 UCB presents latest data from generalized myasthenia gravis portfolio at AANEM meeting

Read More Share:

Aug

17 UCB Partners in Health Economics and Outcomes Research to Evolve Solutions for Seizure Clusters

Read More Share:

Categories

Archives

Dec

23

UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab

Dec

13

Employee Spotlight: Leah VanderVeen and Her Time as a Court Appointed Special Advocate for Foster Children

Dec

07

The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis

Nov

22

UCB Submits Response to FDA Complete Response Letter for Bimekizumab

Nov

14

UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients

Oct

12

Advancing Science to Better Care for Epilepsy Patients

Sep

26

UCB U.S. Headquarters in Atlanta Awarded Prestigious LEED Gold WELL Platinum Certifications

Sep

26

UCB Achieves Two Awards Recognizing our Sustainability Efforts for the Atlanta Warehouse Expansion

Sep

22

UCB presents latest data from generalized myasthenia gravis portfolio at AANEM meeting

Aug

17

UCB Partners in Health Economics and Outcomes Research to Evolve Solutions for Seizure Clusters

Choose Country

UCB in the U.S.

Innovation

Disease Areas

Sustainability

Newsroom

Contact

Categories

Archives

Dec

23

UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab

Dec

13

Employee Spotlight: Leah VanderVeen and Her Time as a Court Appointed Special Advocate for Foster Children

Dec

07

The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis

Nov

22

UCB Submits Response to FDA Complete Response Letter for Bimekizumab

Nov

14

UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients

Oct

12

Advancing Science to Better Care for Epilepsy Patients

Sep

26

UCB U.S. Headquarters in Atlanta Awarded Prestigious LEED Gold WELL Platinum Certifications

Sep

26

UCB Achieves Two Awards Recognizing our Sustainability Efforts for the Atlanta Warehouse Expansion

Sep

22

UCB presents latest data from generalized myasthenia gravis portfolio at AANEM meeting

Aug

17

UCB Partners in Health Economics and Outcomes Research to Evolve Solutions for Seizure Clusters

Choose Country

UCB in the U.S.

Innovation

Disease Areas

UCB Worldwide

Sustainability

Newsroom

Contact